- Home
- GERN vs AMBQ Comparison
GERN vs AMBQ Comparison
Compare GERN & AMBQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GERN
- AMBQ
- Stock Information
- Founded
- GERN 1990
- AMBQ 2010
- Country
- GERN United States
- AMBQ United States
- Employees
- GERN N/A
- AMBQ N/A
- Industry
- GERN Biotechnology: Pharmaceutical Preparations
- AMBQ Semiconductors
- Sector
- GERN Health Care
- AMBQ Technology
- Exchange
- GERN Nasdaq
- AMBQ Nasdaq
- Market Cap
- GERN 823.0M
- AMBQ 673.1M
- IPO Year
- GERN 1996
- AMBQ 2025
- Fundamental
- Price
- GERN $1.27
- AMBQ $32.97
- Analyst Decision
- GERN Buy
- AMBQ Buy
- Analyst Count
- GERN 8
- AMBQ 4
- Target Price
- GERN $3.71
- AMBQ $43.75
- AVG Volume (30 Days)
- GERN 5.5M
- AMBQ 210.2K
- Earning Date
- GERN 11-06-2025
- AMBQ 11-14-2025
- Dividend Yield
- GERN N/A
- AMBQ N/A
- EPS Growth
- GERN N/A
- AMBQ N/A
- EPS
- GERN N/A
- AMBQ N/A
- Revenue
- GERN $164,447,000.00
- AMBQ $74,210,000.00
- Revenue This Year
- GERN $175.15
- AMBQ N/A
- Revenue Next Year
- GERN $56.61
- AMBQ $25.34
- P/E Ratio
- GERN N/A
- AMBQ N/A
- Revenue Growth
- GERN 11877.20
- AMBQ N/A
- 52 Week Low
- GERN $1.09
- AMBQ $31.60
- 52 Week High
- GERN $4.83
- AMBQ $51.76
- Technical
- Relative Strength Index (RSI)
- GERN 41.64
- AMBQ N/A
- Support Level
- GERN $1.23
- AMBQ N/A
- Resistance Level
- GERN $1.33
- AMBQ N/A
- Average True Range (ATR)
- GERN 0.07
- AMBQ 0.00
- MACD
- GERN -0.02
- AMBQ 0.00
- Stochastic Oscillator
- GERN 13.79
- AMBQ 0.00
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.